# Ribbskottet

> Ribbskottet is a VC fund in Stockholm backing Health Care, Biotechnology and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Stockholm, Sweden
- Total investments: 4
- Last investment: Jul 2025
- Lead investor: 0%
- Last updated: Aug 2026

Ribbskottet is an investment company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |
| Hospital | 1 | 25% |
| Medical Device | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 1 | 25% |
| Convertible Note | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Umecrine Cognition | Umecrine Cognition develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids (GABA steroids).Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus thedevelopment activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids).The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome.The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. | $2.6M | Convertible Note | Jul 14, 2025 |  |
| SciBase | Founded in 1998, SciBase AB is a Swedish medical technology company, headquartered in Stockholm, that has developed a unique point of care device for the accurate detection of malignant melanoma.The Scibase method is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of humantissue to categorize cellular structures and thereby detect malignancies. Nevisense is a point-of-care device that has emerged from more than 20 years of academic research at Karolinska Institutet Stockholm and significantly increases the physician’s ability to detect and monitor skin tissue alterations. Nevisense has strong protections through a comprehensive patent portfolio and several other combined approaches that relate to technical and clinical development. | $1.1M | Post-IPO Equity | Jun 23, 2025 |  |
| Umecrine Cognition | Umecrine Cognition develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids (GABA steroids).Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus thedevelopment activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids).The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome.The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. | $2.2M | Convertible Note | Dec 19, 2024 |  |
| Umecrine Cognition | Umecrine Cognition develops drugs against central nervous system neurological disorders, CNS caused by endogenous CNS active steroids (GABA steroids).Umecrine Cognition is a lean organization in a competent network. Together with Karolinska Development, the company was founded in 2006 as a subsidiary to Umecrine AB, in order to focus thedevelopment activities on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids).The GABA-system is the major inhibitory neurotransmitter system within the central nervous system and an excessive GABAergic tone has been described in several important clinical conditions such as Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome. Certain endogenous GABA-steroids act as strong agonists at the GABAA receptor and alterations in the production and metabolism of these GABA-steroids has been described in Hepatic Encephalopathy, Alzheimer’s disease, and Down syndrome.The company is focusing its efforts on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. | $2.9M | Convertible Note | Nov 17, 2023 |  |

4 of 4 investments shown.

## Co-investors
- AB Ility — VC Fund, 3 deals together
- [Karolinska](https://shizune.co/investors/profile/karolinska) — VC Fund, 3 deals together
- Haga Gruppen — VC Fund, 1 deal together
- Life Science Invest Fund — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Ribbskottet invest in?

Ribbskottet invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Equity and Convertible Note stage. Most of the 4 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ribbskottet last invest?

The most recent investment recorded for Ribbskottet closed in Jul 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co